Sam Fazeli

Novo Nordisk's (NVO) next-gen obesity shot (CagriSema) showed 20% weight loss compared to 23% for Eli Lilly's (LLY) drug in a head-to-head trial. NVO stock plunged 15.3% while LLY surged 3.5%. The obesity duopoly is fracturing. Novo "rolled the dice" on a head-to-head comparison and lost, proving their next-gen pipeline is inferior to Lilly's. This erodes Novo's future growth premium (30% of future revenue was tied to this) and cements Lilly as the clinical leader. LONG LLY (Best in Class) / SHORT NVO (Broken Growth Thesis). Regulatory intervention on drug pricing or unexpected side effects in Lilly's broader rollout.

Novo Nordisk's (NVO) next-gen obesity shot (CagriSema) showed 20% weight loss compared to 23% for Eli Lilly's (LLY) drug in a head-to-head trial. NVO stock plunged 15.3% while LLY surged 3.5%. The obesity duopoly is fracturing. Novo "rolled the dice" on a head-to-head comparison and lost, proving their next-gen pipeline is inferior to Lilly's. This erodes Novo's future growth premium (30% of future revenue was tied to this) and cements Lilly as the clinical leader. LONG LLY (Best in Class) / SHORT NVO (Broken Growth Thesis). Regulatory intervention on drug pricing or unexpected side effects in Lilly's broader rollout.